Fritextsökning
Innehållstyper
-
Just four weeks to a concept for an emergency ventilator
The lockdown in spring 2020 meant that the majority of Festo employees had to join the ranks of those working from home. Yet within the space of just four weeks...
-
He is zooming in on topical preparations
According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting ap...
-
Active Biotech tar in pengar
Tar in 55 miljoner till verksamheten genom företrädesemission.
-
Orosmoln för Active Biotech
Avbryter studier med högre doser av laquinimod, bolagets enda kvarvarande kliniska projekt.
-
Failed to read the fine print – lost his life’s work
A celebrated CEO and co-founder of a pioneering lab company one moment – the next, fired, kicked out and written out of the company’s history. This is the story...
-
Marie Gårdmark: Potential step change – EU regulators get to play with data
to the outcome of the pilot to hopefully then understand if “in house” analyses actually will add value.
-
The fast route to a safe insulin pen
Diabetes is on the rise worldwide with around ten million people developing the disease every year. Demand for insulin pens allowing patients to self-medicate i...
-
Neanderthal genes and Nobel Prize in a popular lecture at Bioscience
An inherited gene variant from our ”evolutionary cousins” – the extinct Neanderthals – may affect how our bodies break down certain drugs. “It’s only a matter o...
-
Active Biotech avbryter tasquinimod
Avslutar flaggskeppsprojektet tasquinimod – nu väntar personalminskningar.
-
Tougher competition as the Novo Nordisk Foundation broadens its programme
Søren Nedergaard has worked with innovation at the Danish Government Offices and the University of Copenhagen. Today, he is COO of the Novo Nordisk Foundation, ...
-
Active Biotech ändrar fokus
Slutar med fas III-studier och satsar på tidig utveckling.
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...
-
Anna Törner: Kalashnikovs in a new guise
Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American ph...
-
Ökad förlust för Active Biotech
Efter misslyckandet med flaggskeppsprojektet tasquinimod, som lades ner under våren, fortsätter förlusterna för bioteknikbolaget.
-
Active Biotech håller kursen
Bolaget förväntar sig kunna leverera fas III-data som planerat.
-
The first drugs to slow down Alzheimer’s – but what does it mean for patients?
New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...
-
Fortsatt förlust för Active Biotech
Efter det misslyckade tasquinimod-projektet flyttas fokus till laquinimod och ISI, säger finanschef Hans Kolam.
-
Analytisk kemi nytt ben för Recipharm
CDMO Recipharm lanserar en fristående tjänst inom analytisk kemi.
-
Business Sweden’s new team is rolling out the blue-yellow carpet
According to Business Sweden’s life science team, the combination of substantial medical know-how and an ever-flourishing tech sector is a success factor for Sw...
-
Active Biotech ett hett byte
Blir uppköpta med 15 procents sannolikhet, enligt investmentbanken Goldman Sachs.
-
Negativt för Active Biotech-konkurrenten
Novartis MS-preparat Gilenya når inte målet i fas III.
-
Kassaklirr för Active Biotech
Forskningsbolaget kammar hem delmålsbetalning på 104 miljoner kronor.
-
47 får gå från Active Biotech
Varslar och flyttar allt fokus till laquinimod.
-
Cantargia rekryterar från Active Biotech
Lundabaserade biotechbolaget tar in Göran Forsberg som vd och stärker samtidigt kassan med 20 miljoner.
BREAKING